top of page

Mwandishi:

Mhariri:

Imeboershwa:

ULY CLINIC

ULY CLINIC

17 Februari 2026, 14:31:27

Erysipelas
Erysipelas

Erysipelas

Erysipelas is an acute superficial bacterial infection of the upper dermis and superficial lymphatics, most commonly caused by β-hemolytic streptococci, particularly Streptococcus pyogenes.

It is considered a more superficial and sharply demarcated form of cellulitis.The infection spreads rapidly through lymphatic channels, producing characteristic raised borders.


Most frequently affected sites:

  • Face (classically butterfly distribution)

  • Lower limbs (commonest overall)

  • Arms

  • Umbilical stump (neonates)

The disease has abrupt onset, marked systemic symptoms, and striking skin findings.


Etiology & Microbiology


Main pathogen

  • Streptococcus pyogenes


Less common organisms

Organism

Situation

Group B, C, G streptococci

Elderly & diabetics

Staphylococcus aureus

Secondary infection

Gram-negative bacteria

Immunocompromised patients


Pathophysiology

  1. Entry through skin barrier defect

    • Fissures

    • Tinea pedis

    • Ulcers

    • Surgical wounds

    • Insect bites

  2. Bacterial multiplication in superficial dermis

  3. Lymphatic invasion

    • Causes raised sharply demarcated plaques

  4. Release of streptococcal toxins

    • Fever and systemic toxicity

  5. Inflammatory edema

    • Blistering and hemorrhage


Risk Factors


Local risk factors

  • Tinea pedis (most common portal of entry)

  • Chronic edema / lymphedema

  • Venous insufficiency

  • Skin trauma

  • Surgical wounds


Systemic risk factors

  • Diabetes mellitus

  • Obesity

  • Chronic kidney disease

  • Alcoholism

  • Immunosuppression

  • Elderly age

  • Malnutrition


Recurrence risk factors

  • Previous erysipelas

  • Persistent lymphatic damage

  • Chronic fungal infection of feet


Clinical Features


Prodrome (hours before skin lesions)

  • Fever

  • Chills

  • Malaise

  • Headache

  • Vomiting (children)


Local Skin Findings

  • Rapidly spreading erythematous plaque

  • Raised, sharply demarcated border

  • Warm and tender

  • Edematous swelling

  • Shiny tight skin

  • Burning pain


Advanced Local Findings

  • Superficial blistering (bullae)

  • Petechiae or superficial hemorrhage

  • Lymphangitis streaking

  • Regional lymphadenopathy


Systemic manifestations

  • High fever (38–40°C)

  • Tachycardia

  • Leukocytosis

  • Toxic appearance


Diagnostic Criteria

Diagnosis is primarily clinical.

Major diagnostic features

  • Acute onset fever

  • Raised well-demarcated erythematous plaque

  • Tender swelling

Supportive features

  • Regional adenopathy

  • Blistering due to edema

  • Superficial hemorrhage


Differential Diagnosis

Condition

Distinguishing Feature

Cellulitis

Ill-defined borders, deeper infection

Contact dermatitis

Itchy, not painful, no fever

Deep vein thrombosis

Limb swelling without erythema margin

Necrotizing fasciitis

Severe pain out of proportion, crepitus

Herpes zoster

Vesicles along dermatome


Investigations

Usually not required for uncomplicated erysipelas.


Laboratory tests

Test

Finding

CBC

Leukocytosis

CRP/ESR

Elevated

Blood cultures

Positive in severe cases


Microbiology

  • Skin cultures rarely useful

  • Aspiration culture occasionally performed in severe disease


Imaging

  • Ultrasound: rule out abscess

  • Doppler: rule out DVT

  • CT/MRI: suspected necrotizing infection


Treatment


A. Non-Pharmacological Management

  • Bed rest

  • Elevation of affected limb

  • Compression therapy after acute phase

  • DVT prophylaxis (if immobilized)


B. Local Therapy

  • Weak potassium permanganate soaks (0.025%) twice daily

  • Reduce bacterial load and exudate

Topical options:

  • Silver sulfadiazine cream

  • Mupirocin 2%

  • Fusidic acid 2%

(Topicals are adjuncts — NOT definitive treatment)


C. Systemic Antibiotic Therapy (Main Treatment)


First-line (Streptococcal coverage)

Phenoxymethylpenicillin

  • Adults: 250–500 mg PO every 6 hours × 5–7 days

  • Children: 25 mg/kg every 6 hours

OR

Flucloxacillin

  • Adults: 500 mg PO every 6 hours × 5–7 days

  • Children: 25–50 mg/kg every 6 hours


Severe infection (hospitalized)

  • IV benzylpenicillin or ceftriaxone (not listed but clinically standard)


D. Surgical Treatment

Indicated if complications develop:

  • Secondary abscess → incision & drainage

  • Necrosis → surgical debridement


Complications


Local complications

  • Abscess formation

  • Skin necrosis

  • Ulceration

  • Chronic lymphedema

  • Recurrent erysipelas


Systemic complications

  • Bacteremia

  • Septic arthritis

  • Endocarditis

  • Post-streptococcal glomerulonephritis

  • Toxic shock syndrome


Prevention

  • Treat tinea pedis aggressively

  • Proper wound care

  • Control edema (compression stockings)

  • Skin moisturization to prevent fissures

  • Weight reduction

  • Glycemic control in diabetics


Recurrent erysipelas prophylaxis

Long-term penicillin prophylaxis may be required in frequent recurrence.


Patient Education

Seek urgent care if:

  • Fever >38.5°C

  • Rapid spread of redness

  • Severe pain

  • Blistering or black discoloration

  • Confusion or weakness

Do NOT:

  • Massage affected area

  • Apply irritant chemicals

  • Walk excessively during acute phase


Prognosis

Scenario

Outcome

Early treated

Rapid improvement within 48–72 hrs

Delayed treatment

Recurrence & lymphatic damage

Recurrent disease

Chronic lymphedema

References

  1. Stevens DL, Bisno AL, Chambers HF, et al. Practice guidelines for skin and soft tissue infections. Clin Infect Dis.

  2. World Health Organization. Guidelines for the management of common skin infections. Geneva: WHO.

  3. Habif TP. Clinical Dermatology: A Color Guide to Diagnosis and Therapy. 7th ed.

  4. Fitzpatrick TB, et al. Fitzpatrick’s Dermatology in General Medicine. 9th ed.

  5. Andrews GC, et al. Andrews’ Diseases of the Skin: Clinical Dermatology. 13th ed.

  6. Bolognia JL, Schaffer JV, Cerroni L. Dermatology. 4th ed. Elsevier.

  7. Oxford Handbook of Infectious Diseases and Microbiology. Oxford University Press.

  8. CDC. Group A Streptococcal Skin Infection Guidelines.

  9. IDSA Clinical Practice Guideline for Skin and Soft Tissue Infections.

  10. NICE Guideline: Cellulitis and Erysipelas antimicrobial prescribing.

  11. WHO Essential Medicines List and Antibiotic Recommendations.


Imeandikwa;

3 Novemba 2020, 09:13:42

bottom of page